Bank of America’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,190,864
| Closed | -$47.9M | – | 5676 |
|
|
2026
Q1 | $47.9M | Buy |
1,190,864
+234,091
| +24% | +$5.04M | ﹤0.01% | 1628 |
|
|
2025
Q4 | $24M | Sell |
956,773
-520,752
| -35% | -$12.2M | ﹤0.01% | 2131 |
|
|
2025
Q3 | $33.4M | Sell |
1,477,525
-949,103
| -39% | -$22.1M | ﹤0.01% | 2108 |
|
|
2025
Q2 | $42M | Sell |
2,426,628
-704,808
| -23% | -$13M | ﹤0.01% | 1855 |
|
|
2025
Q1 | $68.5M | Buy |
3,131,436
+1,451,223
| +86% | +$40.1M | 0.01% | 1337 |
|
|
2024
Q4 | $53.6M | Buy |
1,680,213
+705,209
| +72% | +$21.2M | ﹤0.01% | 1433 |
|
|
2024
Q3 | $28.1M | Sell |
975,004
-20,065
| -2% | -$743K | ﹤0.01% | 2075 |
|
|
2024
Q2 | $38.2M | Buy |
995,069
+271,625
| +38% | +$12.3M | ﹤0.01% | 1657 |
|
|
2024
Q1 | $42.5M | Buy |
723,444
+289,107
| +67% | +$18.4M | ﹤0.01% | 1588 |
|
|
2023
Q4 | $26M | Sell |
434,337
-270,618
| -38% | -$13.7M | ﹤0.01% | 1890 |
|
|
2023
Q3 | $26.8M | Buy |
704,955
+295,113
| +72% | +$13M | ﹤0.01% | 1751 |
|
|
2023
Q2 | $37.3M | Sell |
409,842
-197,893
| -33% | -$17.1M | ﹤0.01% | 1522 |
|
|
2023
Q1 | $40.1M | Buy |
607,735
+138,723
| +30% | +$8M | ﹤0.01% | 1528 |
|
|
2022
Q4 | $24.3M | Sell |
469,012
-222,865
| -32% | -$11.8M | ﹤0.01% | 1858 |
|
|
2022
Q3 | $47.3M | Buy |
691,877
+323,561
| +88% | +$19.1M | 0.01% | 1305 |
|
|
2022
Q2 | $16.7M | Sell |
368,316
-13,642
| -4% | -$622K | ﹤0.01% | 2183 |
|
|
2022
Q1 | $19.4M | Buy |
381,958
+107,052
| +39% | +$4.73M | ﹤0.01% | 2162 |
|
|
2021
Q4 | $13M | Sell |
274,906
-5,066
| -2% | -$199K | ﹤0.01% | 2662 |
|
|
2021
Q3 | $9.23M | Buy |
279,972
+39,593
| +16% | +$2.22M | ﹤0.01% | 2943 |
|
|
2021
Q2 | $15.2M | Sell |
240,379
-117,600
| -33% | -$6.07M | ﹤0.01% | 2404 |
|
|
2021
Q1 | $15.4M | Buy |
357,979
+206,354
| +136% | +$9.76M | ﹤0.01% | 2286 |
|
|
2020
Q4 | $8.67M | Buy |
151,625
+27,681
| +22% | +$1.17M | ﹤0.01% | 2619 |
|
|
2020
Q3 | $3.74M | Sell |
123,944
-54,697
| -31% | -$1.63M | ﹤0.01% | 3172 |
|
|
2020
Q2 | $5.83M | Sell |
178,641
-34,479
| -16% | -$1.11M | ﹤0.01% | 2708 |
|
|
2020
Q1 | $5.71M | Buy |
213,120
+18,219
| +9% | +$647K | ﹤0.01% | 2551 |
|
|
2019
Q4 | $5.97M | Buy |
194,901
+45,710
| +31% | +$1.27M | ﹤0.01% | 3068 |
|
|
2019
Q3 | $3.59M | Sell |
149,191
-52,079
| -26% | -$1.43M | ﹤0.01% | 3521 |
|
|
2019
Q2 | $5.1M | Buy |
201,270
+8,643
| +4% | +$176K | ﹤0.01% | 3217 |
|
|
2019
Q1 | $3.76M | Buy |
192,627
+175,094
| +999% | +$2.75M | ﹤0.01% | 3438 |
|
|
2018
Q4 | $231K | Buy |
17,533
+10,407
| +146% | +$160K | ﹤0.01% | 5427 |
|
|
2018
Q3 | $126K | Sell |
7,126
-14,021
| -66% | -$259K | ﹤0.01% | 5758 |
|
|
2018
Q2 | $465K | Buy |
21,147
+20,097
| +1,914% | +$462K | ﹤0.01% | 4948 |
|
|
2018
Q1 | $23K | Sell |
1,050
-330
| -24% | -$6.49K | ﹤0.01% | 6335 |
|
|
2017
Q4 | $30K | Buy |
+1,380
| New | +$20.3K | ﹤0.01% | 6276 |
|
Other funds holding APLS
Bank of America's APLS Position: Q2 2026 in Review
Bank of America sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,190,864 shares — an estimated $47.9M sold.
Bank of America first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $68.5M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Bank of America reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of America sold 1,190,864 Apellis Pharmaceuticals shares in Q2 2026, an estimated $47.9M.
- Bank of America first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Bank of America's Apellis Pharmaceuticals position peaked at $68.5M in Q1 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.